['non small cell lung cancer']
['afatinib', 'cetuximab']

        Principal Inclusion Criteria:

          -  Stage III or IV NSCLC, non irradiable non operable

          -  Non squamous NSCLC histologically or cytologically confirmed

          -  No previous treatment of NSCLC

          -  EGFR mutation (exon 19 deletion, L858R mutation, G719X , L861Q or S768I mutations or
             exon 19 insertion)

          -  Presence of at least one lesion that can be measured

          -  PS 0 or 1

        Principal Exclusion Criteria:

          -  Symptomatic brain metastasis or requiring immediate radiotherapy

          -  T790M mutation or exon 20 insertion

          -  Radiotherapy less than 2 weeks prior randomization including symptomatic radiotherapy

          -  Interstitial pneumopathy
      